^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
Published date:
08/23/2023
Excerpt:
Exelixis...and Ipsen...announced that the global phase 3 CONTACT-02 pivotal trial met one of two primary endpoints, demonstrating a statistically significant improvement in progression-free survival (PFS) at the primary analysis. CONTACT-02 is evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) and measurable soft tissue disease who have been previously treated with one novel hormonal therapy.
Trial ID:
